Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body. This is associated with negative effects on muscle strength, bone density, sexual function, mood, and the ability to think to the best of one's ability. Testosterone replacement therapy often involves injections, patches, or gels that help to raise circulating testosterone levels, but these therapies often have side effects because they lead to imbalance of other hormones. Researchers have been studying the effectiveness of anastrozole, a drug that can lower estrogen levels while simultaneously increasing testosterone levels, as a treatment for the negative effects of decreased circulating testosterone levels that occur naturally with aging. Objectives: To evaluate whether anastrozole is as effective as testosterone gel in improving bone and muscle strength, hormone levels, and brain function in men over 65 years of age. Eligibility: Healthy men at least 65 years of age who have low levels of testosterone. Design: The study involves six study visits over a total of 12 months: screening, baseline, 6 weeks, 3 months, 6 months, and 12 months. All participants will receive calcium and vitamin D supplements to take daily, and will be randomized to one of three groups:Testosterone gel and placebo tablet, Anastrozole tablet and placebo gel, Placebo tablet and gel. Participants will have the following tests at each specified visit:Screening: Blood tests and rectal ultrasound to evaluate the prostate;Baseline: Blood and urine tests; growth hormone levels, muscle strength, bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six weeks: Blood tests and dose adjustment of the gel or tablet;Three months: Blood and urine tests; growth hormone, muscle strength, bone density, and balance evaluation; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six months: Blood and urine tests; muscle strength, bone density, and balance evaluation; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Twelve months: Blood and urine tests; rectal ultrasound; muscle strength, bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Testosterone Trials in Older Men

NCT00799617

Andropause

COMPLETED PHASE3

Testosterone Replacement in Older Men and Atherosclerosis Progression

NCT00287586

Hypogonadism Atherosclerosis

COMPLETED PHASE4

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114

Healthy Volunteers

COMPLETED NA

Testosterone Effects on Bone and Frailty

NCT00182871

Aging Frailty Osteoporosis

COMPLETED PHASE4

Anastrozole Administration in Elderly Hypogonadal Men

NCT00136695

Hypogonadism

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 20% of men over the age of 70 have low testosterone levels. In some studies, testosterone replacement has resulted in improvement in bone mass, muscle strength, quality of life and memory function. In the body, testosterone is converted into estrogen. Hence, it is unclear whether these beneficial effects are due to testosterone or estrogen. Research has shown that inhibition of estrogen production in men results in an increase in testosterone levels.

In this study, patients will be assigned to one of three groups: one group will receive testosterone gel and a placebo tablet, one group will receive a 1mg Anastrozole tablet and a placebo gel, and one group will receive a placebo tablet and placebo gel. Each group will receive a daily dose of calcium with vitamin D. The study requires 6 visits over a 12-month period for testing and evaluation. Two of the 6 visits will require an overnight stay in the hospital so that an intravenous (IV) line can be placed in the arm to allow samples to be drawn throughout the night. Testing will include a cardiac stress test, a glucose tolerance test, bone and muscle tests, evaluation of memory function, etc. For the safety of the prostate, we will perform a prostate ultrasound at the start and end of the study and we will monitor urinary symptoms, prostate specific antigen (PSA) levels and the prostate exam throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypogonadism Diabetes Sarcopenia Osteoporosis Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(Androgel) testosterone gel

17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'

Group Type EXPERIMENTAL

Androgel (Testosterone Gel)

Intervention Type DRUG

1 mg tablet for 12 months

Placebo tablet

Intervention Type DRUG

Daily for 12 months

Calcium Cardone 500mg with vitamin D 400 IU

Intervention Type DIETARY_SUPPLEMENT

1 tablet three times a day

anastrozole (Aromatase inhibitor)

14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'

Group Type EXPERIMENTAL

Anastrozole (Aromatase Inhibitor)

Intervention Type DRUG

Placebo gel

Intervention Type DRUG

Daily for 12 months

Calcium Cardone 500mg with vitamin D 400 IU

Intervention Type DIETARY_SUPPLEMENT

1 tablet three times a day

placebo

13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'

Group Type PLACEBO_COMPARATOR

Placebo tablet

Intervention Type DRUG

Daily for 12 months

Placebo gel

Intervention Type DRUG

Daily for 12 months

Calcium Cardone 500mg with vitamin D 400 IU

Intervention Type DIETARY_SUPPLEMENT

1 tablet three times a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Androgel (Testosterone Gel)

1 mg tablet for 12 months

Intervention Type DRUG

Anastrozole (Aromatase Inhibitor)

Intervention Type DRUG

Placebo tablet

Daily for 12 months

Intervention Type DRUG

Placebo gel

Daily for 12 months

Intervention Type DRUG

Calcium Cardone 500mg with vitamin D 400 IU

1 tablet three times a day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men age 65 years or older
2. Serum testosterone level less than or equal to 350 ng/dl
3. Subject is able to complete an informed consent

Exclusion Criteria

1. History of Stroke
2. History of Dementia
3. History of Diabetes
4. Blood pressure at rest of \> 155/90 mmHg. Elevated systolic or diastolic reading renders subject ineligible
5. Chronic medical condition, i.e. congestive heart failure
6. Arthritis, severe enough to prevent completion of the strength testing, history of joint replacement of knees or hip.
7. Inability to walk 50 meters
8. Known disease of the bone and/or taking medications to treat osteoporosis, i.e.

Fosamax, Evista, Miacalcin
9. History of Gastric surgery
10. History of prostate cancer or any other cancers, including blood dyscrasias
11. History of severe benign prostatic hyperplasia (causing urinary problems)
12. History of heart attack or open-heart surgery within the past 6 months
13. Use of steroids within the past 3 months, including prednisone and/or cortisone injections, and inhaled steroids. Topical steroid cream is acceptable.
14. If you do not agree to refrain from taking the drugs Viagra, Cialis or Levitra for the duration of the study
15. Use of anabolic steroids, i.e. testosterone, (or any analog of testosterone) Dehydroepiandrosterone or any growth promoters i.e. growth hormone itself or analogs of growth hormone
16. Use of anti-androgen medications, i.e. Aldactone, Tagamet, Proscar, estrogens
17. Use of Dilantin or Phenobarbital
18. Alcohol intake \> 30 grams (drink more than 2 beers per day OR more than 1 glass of wine or cocktail daily)
19. Currently smokes any tobacco product
20. Having started a new medication during the past three months which may interfere with the outcome measures of the study
21. Polycythemia
22. Prostate specific antigen \> 4.0 ng/dl
23. Hematocrit \< 36
24. Liver function tests greater than 2 times upper normal limits or abnormal electrolytes, calcium or Parathyroid hormone , at the discretion of the investigator
25. Mini Mental Status Exam score less than or equal to 24

Minimum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes